What's new? Log in Free sign up

Gelteq Limited Ordinary Shares (GELS)

Company Profile

Company profile

Ticker

GELS

Exchange

Website

CEO

Mr. Nathan Jacob Givoni

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

[object Object]

SEC CIK

Corporate docs

Plans of Reorganization

GELS stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Annual report (foreign)

Notice of late annual filing (foreign)

Gelteq Limited Prices US$5.2 Million Initial Public Offering

Certification of approval for exchange listing

Prospectus supplement with pricing info

Registration of securities on exchange

Notice of effectiveness

Registration statement (foreign) (amended)

Registration statement (foreign) (amended)

Registration statement (foreign)

Latest ownership filings

No filings

Financial summary

Financial statements Chart GELS financial data

Quarter (USD)	Jun 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Jun 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

News

From Benzinga Pro

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket

Gelteq Announces That In November, 400,000 Units Of Its Gel Solution Are Entering Into Production; Units Will Fulfill Orders Made For Clients In The U.S And Australia; Delivery Is Expected In January 2025 For Sales Across The Two Countries As Well As In The UAE And In Asia

Press releases

From Benzinga Pro

Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel Technology

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel

Gelteq Receives FDA Approval of its Suitability Petition for New Animal Drug

NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a clinical and biotechnology company focused on developing and commercializing white label gel-based delivery

Gelteq to Participate in the Benchmark Company 13th Annual Discovery Investor Conference

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a clinical and science-based company that is focused on developing and commercializing white label gel-based

Gelteq Announces Largest U.S. Customer Increases Initial Order by 50% to Meet Growing Market Demand

Gelteq Announces 400,000 Units Enter into Production in November 2024

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.